These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 12712409

  • 1. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
    Freedland SJ, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso CL, Belldegrun AS.
    Prostate; 2003 Jun 01; 55(4):299-307. PubMed ID: 12712409
    [Abstract] [Full Text] [Related]

  • 2. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A.
    Cancer J; 2000 Jun 01; 6(4):220-33. PubMed ID: 11038142
    [Abstract] [Full Text] [Related]

  • 3. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer.
    Patel BJ, Pantuck AJ, Zisman A, Tsui KH, Paik SH, Caliliw R, Sheriff S, Wu L, deKernion JB, Tso CL, Belldegrun AS.
    J Urol; 2000 Oct 01; 164(4):1420-5. PubMed ID: 10992426
    [Abstract] [Full Text] [Related]

  • 4. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer.
    Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS.
    Prostate; 2003 Apr 01; 55(1):71-80. PubMed ID: 12640663
    [Abstract] [Full Text] [Related]

  • 5. Reversion of human prostate tumorigenic growth by azatyrosine.
    Benoit RM, Eiseman J, Jacobs SC, Kyprianou N.
    Urology; 1995 Sep 01; 46(3):370-7. PubMed ID: 7660512
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, Choy B, Regan M, Libermann TA, Latham GJ, Sanda MG, Arredouani MS.
    Prostate; 2008 Oct 01; 68(14):1517-30. PubMed ID: 18668517
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T, Lin FF, Rao P, Lin MF.
    Prostate; 2003 Jun 01; 55(4):247-58. PubMed ID: 12712404
    [Abstract] [Full Text] [Related]

  • 10. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME.
    Clin Cancer Res; 2005 Jul 01; 11(13):4905-11. PubMed ID: 16000589
    [Abstract] [Full Text] [Related]

  • 11. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.
    Tepper CG, Gregg JP, Shi XB, Vinall RL, Baron CA, Ryan PE, Desprez PY, Kung HJ, deVere White RW.
    Prostate; 2005 Dec 01; 65(4):375-89. PubMed ID: 16037992
    [Abstract] [Full Text] [Related]

  • 12. Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis.
    Downing S, Bumak C, Nixdorf S, Ow K, Russell P, Jackson P.
    Mol Carcinog; 2003 Nov 01; 38(3):130-40. PubMed ID: 14587098
    [Abstract] [Full Text] [Related]

  • 13. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M, Latham DE, Delaney MA, Chakravarti A.
    Oncogene; 2005 Apr 07; 24(15):2474-82. PubMed ID: 15735703
    [Abstract] [Full Text] [Related]

  • 14. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
    Zhang AL, Russell PJ, Knittel T, Milross C.
    Prostate; 2007 Nov 01; 67(15):1630-40. PubMed ID: 17823933
    [Abstract] [Full Text] [Related]

  • 15. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
    Bhattacharyya RS, Husbeck B, Feldman D, Knox SJ.
    Int J Radiat Oncol Biol Phys; 2008 Nov 01; 72(3):935-40. PubMed ID: 18760546
    [Abstract] [Full Text] [Related]

  • 16. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
    Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers CL.
    Cancer Res; 2005 Dec 15; 65(24):11565-71. PubMed ID: 16357166
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ.
    Cancer Res; 2004 Aug 01; 64(15):5489-95. PubMed ID: 15289359
    [Abstract] [Full Text] [Related]

  • 20. Analysis of differentially expressed genes in LNCaP prostate cancer progression model.
    Xie BX, Zhang H, Wang J, Pang B, Wu RQ, Qian XL, Yu L, Li SH, Shi QG, Huang CF, Zhou JG.
    J Androl; 2011 Aug 01; 32(2):170-82. PubMed ID: 20864652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.